Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Losartan Potassium

FDA-approved product (tablet, oral), marketed as Arbli, Cozaar, Losartan Potassium.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Losartan Potassium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Chronic kidney disease
  • Hypertension
  • Kidney disease
  • Proteinuria
  • Stroke

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Angiotensin ii receptor blockers (arbs), plain
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA47.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli33.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae11.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Losartan Potassium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Losartan Potassium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Losartan and HCTZ and Amlodipine vs Atenolol and Amlodipine (0954A-309)(COMPLETED)

    NCT00140959 · start 2003-02-01

    Registered record
    Registry ID
    NCT00140959
    Conditions
    Hypertension
    Interventions
    MK0954, losartan potassium/Duration of Treatment: 18 weeks; Comparator: losartan, HCTZ, amlodipine, atenolol/Duration of Treatment: 18 weeks
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-02-01
    Completion
    2004-06-30
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionMK0954, losartan potassium/Duration of Treatment: 18 weeks; Comparator: losartan, HCTZ, amlodipine, atenolol/Duration of Treatment: 18 weeks
    PhasePhase 4
    Registry statusCompleted

  • Antihypertensive Efficacy and Safety of Approved Drugs in Japanese Patients With Essential Hypertension (Banyu Study)(0954A-302)

    NCT00092209 · start 2002-04

    Registered record
    Registry ID
    NCT00092209
    Conditions
    Hypertension
    Interventions
    MK0954A, hydrochlorothiazide (+) losartan potassium; Comparator: placebo, losartan, hydrochlorothiazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-04
    Completion
    2002-11
    Enrolment
    840

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionMK0954A, hydrochlorothiazide (+) losartan potassium; Comparator: placebo, losartan, hydrochlorothiazide
    PhasePhase 3
    Registry statusCompleted

  • Health Assessment Study (0954-946)

    NCT00541684 · start 2001-07-11

    Registered record
    Registry ID
    NCT00541684
    Conditions
    Hypertension
    Interventions
    MK0954, /Duration of Treatment : 16 Weeks; Comparator : atenolol /Duration of Treatment : 16 Weeks
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-07-11
    Completion
    2003-01-23
    Enrolment
    143

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionMK0954, /Duration of Treatment : 16 Weeks; Comparator : atenolol /Duration of Treatment : 16 Weeks
    PhasePhase 3
    Registry statusCompleted

  • A Study on Molecular Genetics of Drug Responsiveness in Essential Hypertension

    NCT03276598 · start 1999-11-25

    Registered record
    Registry ID
    NCT03276598
    Conditions
    Hypertension; Pharmacogenetics
    Interventions
    Amlodipine; Bisoprolol; Hydrochlorothiazide; Losartan; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    1999-11-25
    Completion
    2004-04-01
    Enrolment
    233

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Pharmacogenetics
    InterventionAmlodipine; Bisoprolol; Hydrochlorothiazide; Losartan +1 more
    PhasePhase 4
    Registry statusCompleted

  • Inhibitors of Angiotensin II in Proteinuric Mesangioproliferative Glomerulonephritis

    NCT01115426 · start 1997-01

    Registered record
    Registry ID
    NCT01115426
    Conditions
    IGA Glomerulonephritis
    Interventions
    Ramipril or losartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    1997-01
    Completion
    2008-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIGA Glomerulonephritis
    InterventionRamipril or losartan
    PhasePhase 4
    Registry statusCompleted